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The clinical spectrum of the anti-phospholipid syndrome (APS) is not limited to vascular thrombosis or miscarriages
but includes additional manifestations that cannot be explained solely by a thrombophilic state. Anti-cardiolipin,
anti-beta2 glycoprotein I (anti-β2GPI) and lupus anticoagulant (LA) assays are not only the formal diagnostic and
classification laboratory tools but also parameters to stratify the risk to develop the clinical manifestations of the
syndrome. In particular, anti-β2GPI antibodies reacting with an immunodominant epitope on domain I of the
molecule were reported as the prevalent specificity in APS patients, correlating with a more aggressive clinical
picture. Several laboratory assays to improve the diagnostic and predictive power of the standard tests have been
proposed. Plates coated with the phosphatidylserine-prothrombin complex for detecting antibodies represent a
promising laboratory tool correlating with LA and with clinical manifestations. Anti-phospholipid antibodies can be
found in patients with full-blown APS, in those with thrombotic events or obstetric complications only or in
asymptomatic carriers. An inflammatory second hit is required to increase the presence of β2GPI in vascular tissues,
eventually triggering thrombosis. Post-transcriptional modifications of circulating β2GPI, different epitope specificities
or diverse anti-β2GPI antibody-induced cell signaling have all been suggested to affect the clinical manifestations
and/or to modulate their occurrence.Review
The current clinical spectrum of anti-phospholipid
syndrome
Formal clinical classification criteria
The revised classification criteria for anti-phospholipid
syndrome (APS), commonly used as a diagnostic tools
for the syndrome, include a history of venous or arterial
thrombosis and/or of pregnancy morbidity in the pres-
ence of persistent anti-phospholipid antibody (aPL)
positivity (Table 1) [1]. The most common vascular
manifestations are deep venous thrombosis of lower
limbs, pulmonary embolism and cerebral ischemic at-
tack; early and late miscarriages are the major features
of obstetric APS [1,2]. In the catastrophic variant of
APS, multiple small-vessel thrombotic events occur at
different sites, in association with manifestations of the
systemic inflammatory response syndrome [3].* Correspondence: pierluigi.meroni@unimi.it
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2014Clinical manifestations not yet considered as classification
criteria
From the first definition of the disease, the clinical
spectrum of APS has notably extended and many other
manifestations have been described [4]. Thrombocytopenia,
heart valve disease (valve thickening, vegetations and regur-
gitation), nephropathy, livedo reticularis and skin ulcers are
relatively common features of APS but are not included in
the classification criteria because of their low specificity
(Table 2) [5-9].
In addition to thrombo-occlusive events in the cerebral
circulation, a wide range of 'non-criteria' neurological
manifestations have been associated with aPL, even
though in some cases such association is still controver-
sial. Examples include untreatable headache and migraine,
epilepsy, chorea, ocular manifestations such as amaurosis
fugax and retinal vessel thrombosis [10,11]. A clinical syn-
drome and/or magnetic resonance imaging resembling
multiple sclerosis has also been described in APS, raising
the issue of a correct differential diagnosis [10].Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
ime, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Revised classification criteria for anti-phospholipid syndrome [1]
Clinical criteria
Vascular thrombosis One or more episodes of arterial, venous or small vessel thrombosis in any tissue or organ
(confirmed by objective validated criteria (imaging study or histopathology))
Pregnancy complications One or more unexplained deaths of a morphologically normal fetus ≥10th gestational week
One or more premature births (≤34th gestational week) of a morphologically normal neonate
because of eclampsia, severe pre-eclampsia or placental insufficiency
Three or more unexplained consecutive spontaneous abortions ≤9th gestational week (maternal
anatomic and hormonal abnormalities and chromosomal abnormalities excluded)
Laboratory criteria
Lupus anticoagulant present in plasma Detected according to the guidelines of the International Society of Thrombosis and Haemostasis
(Scientific subcommittee on lupus anticoagulant/phospholipid-dependent antibodies)
IgG and/or IgM anti-cardiolipin antibodies in
serum of plasma
At medium/high titer (≥40 GPL or MPL or ≥99th percentile) measured by standard ELISA
IgG and/or IgM anti-β2 glycoprotein I
antibodies in serum or plasma
Titer ≥99th percentile measured by standard ELISA, according to recommended procedures
At least one clinical and one laboratory criterion is mandatory. Autoantibodies have to be confirmed on two or more occasions at least 12 weeks apart. ELISA,
enzyme-linked immunosorbent assay; GPL, IgG aPL units; Ig, immunoglobulin; MPL, IgM aPL units.
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impairment in systemic lupus erythematosus (SLE) pa-
tients, even if recent studies in very large SLE cohorts
have not confirmed such an association [11]. Although
scant, studies in primary APS have reported a high pre-
dominance of cognitive deficits involving attention and
verbal fluency [12,13]. In addition, several authors re-
ported the occurrence of chronic or recurrent ischemic
events affecting small or large cerebral vessels and lead-
ing to multi-infarct dementia [1].
Further manifestations affecting different organs or tis-
sues have been described in APS patients. However, their
association with aPL is still a matter of research mainly be-
cause of the anecdotal nature of the reports or the presence
of other underlying disorders (diffuse alveolar hemorrhage,
myocardial dysfunction, transverse myelopathy, Guillain-
Barré syndrome and multiple mononeuropathy, sensori-
neural hearing loss or vertigo due to middle ear involve-
ment, splinter hemorrhages and anetoderma [1]).
Diagnostic laboratory tools
Classification laboratory assays
Laboratory criteria for formal APS classification cur-
rently include three aPL assays: one based on coagula-
tion tests to reveal the presence of lupus anticoagulant
(LA) and two solid phase assays to detect IgG/IgM anti-
bodies targeting cardiolipin (CL)/beta2 glycoprotein I
(β2GPI) complexes or β2GPI alone (Table 1). Persistent
medium/high positivity (12 weeks apart) of at least one
of these tests is mandatory [1].
Risk stratification
According to the revised classification criteria, APS pa-
tients should be divided into four categories: category I
includes patients with more than one positive test in anycombination, while patients with a single positive test
should be classified in category II (IIA if LA-positive, IIb
if positive for antibodies against CL (aCLs), IIc if positive
for anti-β2GPI antibodies) [1]. Triple positivity, defined
by the presence of LA and medium/high titers of aCL
and anti-β2GPI antibodies (above the 99th percentile), is
the most predictive profile for clinical manifestations
and recurrences despite conventional treatment [14,15].
There is growing evidence that patients in category II
have a lesser risk to develop APS manifestations. LA was
reported to be the most predictive test. LA can be medi-
ated by both anti-β2GPI and anti-prothrombin (aPT)
antibodies [16]. However, β2GPI-dependent LA was
found to be a stronger risk factor for thrombosis and
miscarriages than aPT-dependent LA [17,18]. aCL posi-
tivity alone is not associated with an increased risk of
thrombosis or pregnancy loss [16,17,19]. Data on anti-
β2GPI antibodies are more controversial, maybe because
the assay is less standardized [17]. Accordingly, Otomo
and colleagues [20] have recently validated a scoring sys-
tem to quantify the thrombotic or obstetric risk depend-
ing on aPL profiles.
Clinical events are more robustly associated with aPLs of
the IgG isotype, an isolated positivity for aCLs or anti-
β2GPI antibodies of the IgM isotype being rarely detected
in APS cohorts. Patients carrying both aCL/anti-β2GPI
antibody isotypes display a higher risk of developing clinical
events [21]. Some investigators have recently proposed that
aCLs and anti-β2GPI IgA antibodies be included in the
APS laboratory criteria. However, this is not supported by
available data: the detection of a single IgA aPL positivity is
more commonly associated with non-criteria manifesta-
tions, while IgA testing has not been shown to increase the
diagnostic accuracy for APS [22]. Interestingly, this is not
consistent with in vivo findings, which are supportive for a
Table 3 Future research requirements for the most promising non-classification laboratory assays
Test Assay Future research needs
Anti-DI antibodies ELISA Analytical and post-analytical standardization
CIA Retrospective and prospective clinical validation
Anti-PS/PT antibodies ELISA Analytical and post-analytical standardization
Retrospective confirmatory studies and prospective clinical validation
Anti-PE antibodies ELISA Analytical and post-analytical standardization
Retrospective confirmatory studies and prospective clinical validation
Annexin A5 resistance assay Two-step coagulation assay Analytical and post-analytical standardization
Retrospective and prospective clinical validation
CIA, chemiluminescence immunoassay; DI, domain I; ELISA, enzyme-linked immunosorbent assay; PE, phosphatidylethanolamine;
PS/PT, phosphatidylserine-prothrombin.
Table 2 Anti-phospholipid syndrome clinical manifestations not yet considered as classification criteria
Frequency
Clinical manifestations PAPS APS-SLE Notes
Thrombocytopenia 20-25% 30-40% Usually mild
No protective effect on thrombotic risk
Heart valve disease 12-33% 40% Possibly an additional risk for secondary
thromboembolism
Skin
Livedo reticularis 20-25% 35% Original association with arterial thrombosis not
confirmed in prospective studies
Ulcers 33% 7-10% Pre-tibial area
Frequently observed in catastrophic APS
Superficial thrombophlebitis 9% Reported in aPL-positive patients but their value still
debated
Kidney
Renal artery stenosis 26% of aPL + patients with uncontrolled
hypertension
Resulting in severe renovascular hypertension, renal
infarcts
APS nephropathy (renal small
artery vasculopathy, involving
both arterioles and glomerular capillaries)
35%a 39-67% a Association with pregnancy complications, extra-
renal vascular thrombosis and higher risk of chronic
renal failure among SLE patients
Central nervous system
Migraine/headache 20% 25% Controversial association with aPLs because of the
high prevalence in the general population
Epilepsy 6-7% 14% In many but not all cases secondary to ischemic
events
Conflicting data on relationship between aPLs and
seizure in SLE
MS-like disease No definite data regarding prevalence because of the
difficult differential diagnosis
Cognitive impairment 38% 48% Mostly involving attention and verbal fluency
Dementia 2.5-56% Resulting from chronic or recurrent ischemic events
Ocular manifestations 15-88% Amaurosis fugax as potential first sign of cerebral
ischemia
Retinal artery thrombosis vessels (arteries and veins)
are relatively frequent and can lead to significant
visual loss
Transverse myelopathy 1% Strong correlation with aPLs in SLE patients
Pulmonary alveolar hemorrhage <1% Very poor prognosis
aData from small series, with hypertension or signs suggestive of nephropathy. aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; MS, multiple
sclerosis; PAPS, primary anti-phospholipid syndrome; SLE, systemic lupus erythematosus.
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Table 4 Studies addressing prevalence and clinical association of aPT antibodies
Reference Study population N Prevalence of anti-PT Clinical association
Fleck et al. [28] LA positive subjects 42 74% NI
Pengo et al. [29] APS patients 22 50% No association with thrombosis
Horback et al. [30] SLE patients 175 38% Association with thrombosis(IgG and IgM)
Puurunen et al.
[31]
SLE patients 139 34% Association with DVT
Swadzba et al. [32] SLE patients with thrombotic
event
127 28% No association with thrombosis (IgG and IgM)
31
Galli et al. [33] aPL-positive subjects 59 58% No association with thrombosis
IgG 35.6%
IgM 37.3%
Bertolaccini et al.
[34]
SLE patients 207 28% No association with APS clinical manifestations
Forastiero et al.
[35]
APS patients 97 25% Association with thrombosis
aPL-negative patients with
thrombotic events
83
Munoz-Rodriguez
et al. [36]
APS patients 70 57% Association with arterial thrombosis (IgG only)
SLE patients 107 40%
Atsumi et al. [37] Patients with autoimmune
diseases
265 IgG: PAPS 15%; SLE APS 42%;
SLE no APS 20%
No association with APS
IgM: PAPS 5%; SLE APS 4%; SLE
No APS 6%
Galli et al. [38] LA-positive patients 72 85% No association with APS
Nojima et al. [39] SLE patients 124 IgG 52.4% Association with venous thromboembolism (only aPT
IgG + LA)
IgM 21%
Nojima et al. [40] SLE patients 168 56% Association with arterial thrombosis
Simmelink et al.
[41]
LA-positive patients 46 30% Association with thrombosis
LA-positive patients with SLE 29 LA-positive subjects: 70%
LA-negative patients 38
LA-negative patients with SLE 36
Salcido-Ochoa et
al. [42]
APS patients 38 IgG 26%, IgM 11% Association with thrombosis
SLE patients 466 IgG 20%, IgM 33%
Von Landenberg
et al. [43]
APS patients 170 IgG 61.7% Association with pregnancy loss (IgG only)
(57% PAPS; 43% SAPS) IgM 57.6%
IgA 7%
Musial et al. [44] APS patients 22 IgG 45.4%, IgM 50% No association with thrombosis
SLE patients 160 IgG 18.1%, IgM 18.7%
SLE-like patients 22 IgG 31.8%, IgM 27.3%
Ishikura et al. [45] SLE patients 22 18.2% Association with venous thrombosis
Patients with
DVT/PTE 48 IgG 29%, IgM 8.3%
Stroke 30 IgG 16.7%, IgM 6.7%
Koskenmies et al.
[46]
SLE patients 292 20% Association with arterial thrombosis
Bertolaccini et al.
[47]
SLE patients 212 31% Association with venous/arterial thrombosis (IgG only)
IgG-only 24.5%
IgM-only 5%
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Table 4 Studies addressing prevalence and clinical association of aPT antibodies (Continued)
Bizzarro et al. [48] aCL-positive APS patients 25 60% Association with thrombosis (IgG only)
SLE-APS patients 23 45%
SLE-no APS patients 66
Forastiero et al.
[49]
aPL-positive subjects (LA/aCL) 194 46% Association with thrombosis (IgG only)
IgG 36%
IgM 23%
Gould et al. [50] SLE patients 100 20% No association with thrombosis
Tsutumi et al. [51] SLE patients 139 25% Association with thrombosis
Nojima et al. [52] SLE patients 175 54.3% No association with thrombosis
Bizzaro et al. [53] SLE patients 101 IgG 13.9% Association with thrombosis (IgG only)
IgM 9%
IgG + IgM 3%
Sailer et al. [54] LA-positive subjects 79 No association with thrombosis
With thrombosis 50 72% (assay I), 50% (assay II)
Without thrombosis 29 66% (assay I), 41% (assay II)
Bardin et al. [55] APS patients 62 42% NI
Jakowski et al. [56] APS patients 58 22% No association with pregnancy loss
Women with recurrent
pregnancy loss
66 12%
Szodoray et al. [57] SLE patients 85 IgG 18%, IgM 0 NI
Pengo et al. [58] LA-positive subjects 231 IgG 26% No association with APS clinical events
IgM 27%
Marozio et al. [59] Obstetric APS patients 187 29.4% Association with severe pre-eclampsia, HELLP syn-
drome, intra-uterine fetal death
IgG 25.8%
IgM 1.8%
IgG + IgM: 1.8%
Hoxha et al. [60] PAPS patients 158 IgG 23.5%, IgM 4.9% Association with thrombosis and obstetric
manifestations (IgG only)
Thrombotic APS 56 IgG 10.7%, IgM 1.8%
Obstetric APS 102
Sater et al. [61] Women with recurrent
miscarriages
277 IgM 12% No association with pregnancy loss
aCL, anti-cardiolipin antibody; aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; aPT, anti-prothrombin antibody; DVT, deep vein thrombosis;
HELLP, hemolysis, elevated liver enzymes and low platelet count; Ig, immunoglobulin; LA, lupus anticoagulant; NI, not investigated; PAPS, primary anti-
phospholipid syndrome; PTE, pulmonary thromboembolism; SAPS, secondary anti-phospholipid syndrome; SLE, systemic lupus erythematosus.
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thrombus formation [23].
While it is well accepted that aPLs confer a prothrom-
botic susceptibility when at high titers, controversies
have recently arisen about the clinical meaning of low-
titer aPLs in pregnancy morbidity. A few studies have re-
ported that women with persistent low-titer aPL positiv-
ity display an obstetric outcome comparable to the
general population [17]. On the other hand, a recent
study showed that low-titer aCL and anti-β2GPI anti-
body positivity (between the 95th and 99th percentiles)
accurately identifies women with aPL-related pregnancy
complications [24].Risk stratification for thrombotic events should also
take into account the presence of traditional cardiovas-
cular factors such as systemic inflammatory conditions
(infectious or autoimmune), inherited thrombophilia, ar-
terial hypertension, cigarette smoking and dyslipidemia
[1]. Risk-factors for pregnancy failure include low com-
plement levels, decreased platelet counts and a previous
history of thrombosis and pregnancy failure [15].
Non-classification laboratory assays
Additional laboratory tests to detect aPLs have been re-
ported: the most important 'non-classification' tests still
deal with the two major phospholipid (PL)-binding
Table 5 Studies addressing prevalence and clinical association of aPS/PT antibodies
Reference Studied population N Prevalence of anti-PS/PT Clinical association
Galli et al. [33] aPL-positive subjects 59 90% No association with thrombosis
IgG 75%
IgM 66%
Atsumi et al. [37] Patients with autoimmune
diseases
265 IgG: PAPS 19%; SLE APS 63%; SLE-no
APS 13%
Association with APS
IgM: PAPS 10%; SLE APS 29%; SLE-no
APS 4%
Nojima et al. [62] SLE patients 126 38.1% No association with stroke
Bertolaccini et al.
[47]
SLE patients 212 31% No association with thrombosis
IgG-only 16%
IgM-only 6%
Tsutumi et al. [51] SLE patients 139 21% Association with thrombosis
Nojima et al. [52] SLE patients 175 43.4% Association with thrombosis
Bardin et al. [55] APS patients 62 55% NI
Jakowski [56] APS patients 58 44% No association with pregnancy loss
Women with RPL 66 1%
Atsumi et al. [63] Patients with autoimmune
diseases
441 18.3% Association with APS
PAPS 84 39%
SLE-APS 68 47%
SLE-no APS 136 10%
Rheumatoid arthritis 46 0
Sjogren syndrome 36 0
Other 71 4%
Žigon et al. [64] APS patients 100 59% NI
Vlagea et al. [65] PAPS patients 98 51%, IgG 35.7%, IgM 32.6% Association with venous thrombosis and obstetric
morbidity
SAPS patients 45 53.3%, IgG 40%, IgM 31.1%
aPL-positive subjects 57 38.6%, IgG 21.1%, IgM 26.3%
Pregnolato et al.
[26]
APS patients 80 81.3% Association with venous thrombosis (IgG only)
aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; aPS, anti-phosphatidylserine antibodies; Ig, immunoglobulin; NI, not investigated; PAPS, primary
anti-phospholipid syndrome; PS, phosphatidylserine; PT, prothrombin; RPL, recurrent pregnancy loss; SAPS, secondary anti-phospholipid syndrome; SLE, systemic
lupus erythematosus.
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for aPL: β2GPI and prothrombin (PT) [16]. However,
other autoantigens have been described that are a matter
of debate and research (Table 3).
Anti-prothrombin antibodies
To be antigenically recognized, human PT has to be either
coated on activated plates or exposed to immobilized an-
ionic phosphatidylserine (PS) via calcium ions. ELISAs to
detect antibodies against the PS/PT complex (aPS/PT anti-
bodies) identify a partially different autoantibody popula-
tion from the assay using PT as the only antigen [25]. A
contentious issue concerns the potential cross-reactivity
between aPS/PT and anti-β2GPI antibodies; however, hu-
man anti-β2GPI monoclonals or affinity-purified anti-β2GPI polyclonal IgG antibodies obtained from a serum
reacting with both β2GPI and PS/PT have been shown to
react towards β2GPI only [26].
In vitro experimental findings suggest that aPTs exert
thrombogenic effects interfering with fluid phase com-
ponents of coagulation and activating endothelial cells
(ECs). Evidence from animal models is rather weak,
however, mainly because of the lack of cross-reactivity of
human aPTs with animal PT [25].
The wide variability in epitope specificities and detec-
tion methods drives a disparity across available studies
about the prevalence and clinical significance of aPTs.
The prevalence of antibodies targeting PT depends also
on selection of study populations: when considering
solely individuals with LA, the positivity rate increases
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[25]. Similarly, the clinical significance of aPTs in both
primary and secondary APS is still a matter of debate.
Some studies showed that aPTs are an independent risk
factor for either venous or arterial thrombosis, while
others have failed to demonstrate such an association.
On the other hand, most of the studies addressing the
clinical significance of aPS/PTs have highlighted a sig-
nificant association with aPL-associated manifestations,
in particular venous thrombosis. Consistently, a system-
atic review did not find any correlation between aPTs
and clinical events, while a more recent one found that
aPS/PTs are a stronger risk factor for arterial and venous
thrombosis than aPTs [27]. Much more controversial re-
mains the association of aPTs and aPL-related pregnancy
morbidity (Tables 4 and 5).
aPS/PTs have been proposed as a surrogate test for LA
and as an additional serological marker of APS, to be
performed with other aPL tests to improve diagnosis.
Noteworthy, LA together with aβ2GPI and aPS/PT anti-
bodies has recently been identified to display the best
diagnostic accuracy for both vascular and obstetric APS
among 23 possible combinations of six aPL assays (LA,
aCLs, anti-β2GPI antibodies, aPTs, aPS/PTs, and anti-
phosphatidylethanolamine antibodies (aPEs)) [66]. How-
ever, the bulk of evidence is still not solid enough to rec-
ommend routine testing for antibodies targeting PT as
shown by a summary of all studies available in the litera-
ture (Tables 4 and 5).
New assays for anti-β2GPI antibodies: the anti-domain
antibodies
β2GPI is a relatively large plasma glycoprotein of 70 kDa
with good immunogenic properties. Thus, it is not sur-
prising that APS patients can produce antibodies against
several epitopes of the molecule as demonstrated using
different experimental approaches. Although the epitope
specificity using linear peptides was not originally re-
ported to be associated with specific clinical manifesta-
tions of the syndrome, more recently a close association
between anti-domain (D)I reactivity and vascular events
has been suggested [67].
The reactivity against DI of β2GPI was described for the
first time in 2002 but its importance was revealed when a
two-step technique was used to characterize β2GPI-
dependent aPLs [68]. Specifically, β2GPI coated on hydro-
philic but not hydrophobic microtiter plates displays con-
formational changes that expose DI to the surface, making
it more accessible for autoantibody binding. Anti-β2GPI
antibodies with DI specificity were found in the majority
of APS patients and were significantly associated with LA
and vascular thrombosis (mostly venous) [69]. Only in a
subsequent multicenter study were they also found to be
associated with the obstetric manifestations of thesyndrome, although to a lesser extent than with throm-
bosis [70]. However, some data from the multicenter study
are controversial. In fact, no correlation between LA and
miscarriages was found, in contrast to several previous
publications and the known clinical LA predictive value
for miscarriages [17]. High levels of antibodies with com-
parable specificity and detected by a research ELISA kit
have been recently associated with an increased risk for
thrombotic events in a prospective cohort of SLE or aPL
patients by the same group [71].
Recent studies have demonstrated that patients with
multiple positive test results (that is, LA, aCLs and anti-
β2GPI autoantibodies particularly of the IgG isotype)
display a much higher risk for developing clinical com-
plications [17]. In line with the hypothesis that anti-DI
IgG may represent a more predictive aPL profile, these
patients tend to have a higher prevalence and higher ti-
ters of anti-β2GPI-DI antibodies [72,73].
Anti-β2GPI-DI IgG antibodies have been found as the
most prevalent antibodies not only in primary APS with
thrombosis but also in primary APS with pure obstetric
disease. Comparable positivity rates were detectable in
patients with SLE or undifferentiated connective tissue
diseases, while antibodies against DIV or DV were less
frequent in the same populations [73]. aPL positive
asymptomatic carriers display a less polarized profile,
suggesting that anti-DI antibodies may cluster in pa-
tients with systemic autoimmune diseases [73]. Interest-
ingly, the two techniques for anti-DI antibodies used in
the study (that is, standard ELISA and chemilumines-
cence immunoassay (CIA)) have been reported to dis-
play the same specificity but different sensitivities [74].
Additional epidemiological studies apparently support
the diagnostic/predictive value of anti-DI antibodies. IgG
reacting with β2GPI in sera from aPL-positive asymp-
tomatic carriers, individuals with leprosy or children
with atopic dermatitis have been shown to preferentially
recognize epitopes on DIV or DV [68]. Recent studies
have suggested that the ratio between anti-β2GPI-DI and
anti-β2GPI-DIV/V IgG antibody reactivities can provide
important information to discriminate between anti-
β2GPI antibodies linked to an autoimmune disease such
as APS and antibodies occurring in association with
other pathologies [73]. If confirmed in larger studies, this
finding would suggest the use of tests for antibodies
against the different domains to discriminate between
predictive versus non predictive anti-β2GPI antibodies.
In any case, it is difficult to draw definite conclusions
on the diagnostic and prognostic value of anti-DI anti-
bodies at this stage. The high prevalence of anti-DI IgG
antibodies in patients with medium-high titers of aPLs
and multiple positivities in the formal diagnostic tests
supports the role of DI as the immunodominant epitope
of β2GPI. However, a small but consistent proportion of
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with different epitopes, suggesting that the assay for the
whole molecule cannot be substituted yet [73]. The dis-
crepancies in the clinical associations can be related to
the different methodologies used. Besides the two-step
assay, three ELISA studies and a CIA employing differ-
ent DI molecules or peptides have been reported [74,75].
Although preliminary data seem to indicate that the
solid phase assays by two different ELISAs or CIA are
comparable, there is no information on the comparison
with the two-step assay and the additional ELISAs. Con-
firmatory studies using multi-center setups and larger
prospective patient cohorts are needed to confirm the
data.
The fact that the anti-DI antibodies are directed against
the immunodominant epitope of β2GPI is supported also
by pathogenic studies in animal models. Passive infusion
of a synthetic antigenic target peptide DI was shown to
protect naïve mice from the thrombogenic effects of hu-
man polyclonal aPL IgG fractions [76]. Although the in-
hibition of thrombus formation as well as expression of
adhesion molecule on aortic ECs and tissue factor expres-
sion on macrophages were not complete, this finding was
thought to represent a proof of concept of the pathogenic
role of anti-DI antibodies [76]. More recently, a human
monoclonal IgG, specifically reacting with DI, was shown
to induce clotting and fetal loss in naïve mice, offering the
first direct demonstration of the pathogenic effect of anti-
DI antibodies [77]. Interestingly, the anti-DI monoclonal
induced clotting via complement activation and only after
the concomitant administration of small amounts of lipo-
polysaccharide. This finding is in line with previous results
obtained using polyclonal IgG anti-β2GPI fractions from
APS patients and further supports the potential patho-
genic role of anti-DI antibodies.
The main epitope of DI has been suggested to be a
cryptic and conformation-dependent structure involving
different residues located in the proximity of the junc-
tion between DI and DII. Fine epitope mapping using
short synthetic peptide fragments and mutation experi-
ments have demonstrated that the main epitope on
β2GPI-DI is located around amino acid 40 of the mol-
ecule with R39-R43 representing the key constituent of
the discontinuous epitope [68]. DI of β2GPI is usually
hidden, being linked with DII in the circular form of the
molecule, the most abundant variant in the circulation.
After interaction with anionic PL monolayers or when
bound to endotoxin, β2GPI is opened and DI can be pre-
sented to the afferent limb of the immune system [69].
In other words, it could be speculated that, unlike the
other domains, which can induce tolerance at high anti-
gen concentrations, DI does not. So, even a small
amount of DI presented to the immune system can
break the tolerance and easily induce specific antibodies.Antibodies against phosphatidylethanolamine
Phosphatidylethanolamine (PE) is a zwitterionic PL,
mainly located in the inner leaflets of biological mem-
branes. Subpopulations of aPE bind to high molecular
weight kininogen, leading to the formation of antibody-
PE-kininogen trimolecular complexes that enhance
thrombin-induced platelet aggregation. PE promotes
thrombosis by activating factor X and PT, and works as
an anticoagulant potentiating activated protein C activ-
ity. The finding that PE in the hexagonal phase inhibits
the prolongation of clotting time led to the hypothesis
that aPEs might be responsible for the LA phenomenon,
despite a lack of a significant association between the
two assays [78]. A clear in vivo demonstration of the
pathogenic role of aPEs in mediating vascular and ob-
stetric events is lacking.
Antibodies against PE have been described in up to
43% of APS patients, a higher positivity rate compared
to healthy controls [78]. In particular, aPE prevalence
among women experiencing recurrent pregnancy loss
(RPL) has been reported to range between 23 and 31.7%
[79]. Overall, available evidence on the clinical role of
aPEs is inconsistent and comes from a limited number
of studies, being flawed by the small sample size and
poor ELISA standardization [78]. Therefore, aPE testing
is currently not recommended, with these autoantibodies
not yielding increased accuracy in diagnosing APS.
Nevertheless, some authors have proposed aPEs as sero-
logical markers of seronegative APS, a debated noso-
logical entity characterized by a clinical picture highly
suggestive of APS despite persistent aPL undetectability.
In patients with otherwise unexplained thrombotic
events, the prevalence of aPEs was 18% when detected
by ELISA, rising to 30.5% when tested using thin-layer
immunostaining [78,80]. Further, in a multicenter study
on 270 thrombotic patients, 63% of 40 aPE-positive sub-
jects had no additional aPL laboratory tests [78].
Antibodies against anionic phospholipids other than
cardiolipin
The diagnostic and prognostic roles of several autoanti-
bodies targeting negatively charged PLs other than CL
have been evaluated, though not extensively, in the set-
ting of APS.
PS, phosphatidylinositol and phosphatidic acid, three
anionic PLs found in the inner and outer membranes of
most cells, are among the best-characterized antigens.
Noteworthy, in the 1980s aCLs were shown to broadly
cross-react with antibodies targeting both PS and phos-
phatidylinositol. The cross-reactivity was mostly sup-
ported by the recognition of the complex of β2GPI with
the different anionic PLs. In fact, being a cationic mol-
ecule, β2GPI binds efficiently to negatively charged PLs.
Hence, the largest part of the cross-reactivity is actually
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reacting with β2GPI [81]. As a whole, testing for anti-
bodies against PS (aPSs), phosphatidylinositol and phos-
phatidic acid does not improve the likelihood of
diagnosing APS compared with criteria tests, being there-
fore not recommended in international guidelines [1].
Nevertheless, aPSs were reported to be promising,
with a particular relevance in obstetric APS. In a study
on 872 women with RPL, aPSs were the only detectable
aPLs in 3.6% of subjects [82]. However, contradictory
data have recently emerged: in one study, aPSs were not
related to RPL, while other authors identified IgG but
not IgM aPSs as associated with RPL. On the other
hand, there is no evidence for an association between
aPSs and vascular events [82].
Two murine monoclonal antibodies targeting PS (one
reacting with both CL and PS and one with PS only)
inhibited the development and invasion by trophoblasts,
decreased human chorionic gonadotropin levels and re-
tarded syncytiotrophoblast formation. Unfortunately there
is no information whether they recognized β2GPI or not
[82]. Conversely, the β2GPI dependence was shown to be
important in another study in which active immunization
with β2GPI-dependent polyclonal human IgG but not IgM
aPSs induced fetal resorption via the production of murine
β2GPI-dependent IgG aPSs [83]. Discrepancies across
available studies justify why APS criteria do not include
aPS assays among laboratory tools.
A novel ELISA kit detecting antibodies against a mix-
ture of negatively charged PLs comprising PS, phospha-
tidic acid and β2GPI (APhL) has been recently
introduced to the market. This commercial immuno-
assay has been suggested to overcome the issue of the
low specificity of aCLs, which are frequently detected in
infectious conditions such as chronic hepatitis C, lep-
rosy, syphilis, and parvovirus B19 infection among
others. Furthermore, the APhL assay displays higher
positive and negative predictive values for APS diagnosis
compared to two commercially available aCL assays
[84]. In a cohort of 158 SLE patients, multivariate ana-
lysis revealed an association between APhL and throm-
botic events, particularly arterial [85].
Antibodies against vimentin
Proteomic analysis of endothelial-surface membrane
proteins in sera from patients with so-called seronega-
tive APS led to the identification of vimentin as a strong
autoantigen. Vimentin, a ubiquitous cytoskeleton inter-
mediate filament protein, has been shown to bind CL
in vitro. In one cohort of patients, antibodies against
vimentin/CL were described in 55% of seronegative APS
and 92% of full-blown APS patients [82]. However, anti-
bodies against vimentin/CL have also been reported in
aPL-negative SLE and rheumatoid arthritis subjectswithout any clinical manifestation suggestive of APS,
thus weakening the specificity of such a diagnostic
marker [82].
Annexins: annexin A5 resistance assay and
autoantibodies against annexin A5 and annexin A2
Annexins are a family of ubiquitous calcium-dependent
PL-binding proteins. Annexin (Ann)A5 is a potent anti-
coagulant protein mainly found in trophoblasts and vas-
cular ECs. Upon binding to anionic PLs, it undergoes
oligomerization to form a protective shield against co-
agulation enzymes. β2GPI-dependent aPLs have been
shown to interfere with the protective binding of AnnA5
to the endothelium, hence leading to thrombosis. A
novel two-stage coagulation assay to establish the
AnnA5 resistance has been developed; patients with co-
agulation time lower than the reference are considered
AnnA5-resistant [81,82]. Data from five studies revealed
that 52% of APS patients were AnnA5-resistant, in com-
parison with 2 to 5% of controls and seronegative sub-
jects [81]. Resistance to AnnA5 anticoagulant activity
was found to inversely correlate with titers of IgG anti-
bodies targeting DI in both thrombotic and obstetric
APS [81]. Future studies will assess whether this func-
tional test may allow the identification of specific subsets
of pathogenic anti-β2GPI antibodies. The clinical signifi-
cance of serum autoantibodies against AnnA5 has also
been investigated: in one study, no association was re-
ported between these autoantibodies and vascular
events, while inconsistencies emerged across different
studies in obstetric APS [81,82].
AnnA2, a cofactor for plasmin generation and cell-
surface localization of fibrinolytic activity, has been iden-
tified as a receptor mediating β2GPI binding to ECs.
Autoantibodies against AnnA2 have been demonstrated
to exert a prothrombotic activity by activating ECs, in-
ducing tissue factor expression and blocking tissue plas-
minogen activator-induced plasminogen activation
in vitro. A high prevalence of AnnA2 antibodies has
been described in patients with APS, but also in some
other autoimmune conditions, thus lowering the specifi-
city of this biomarker [86].
More than just autoantibodies
The presence of aPLs, even if persistent over time, does
not explain the full spectrum of APS. For example, a
comparable aPL profile can be associated with vascular
but not obstetric manifestations and, in some cases,
women with APS and previous miscarriages do not dis-
play any vascular events [1,4]. In other words, autoanti-
bodies with the same autoantigen specificity and titers
have been associated with different clinical pictures and
found to support diverse pathogenic mechanisms in ex-
perimental models [16].
Figure 1 Schematic views of anti-phospholipid syndrome pathogenic mechanisms. (a) Vascular anti-phospholipid syndrome (APS). Anti-
phospholipid antibodies (aPLs) may target different cell types and soluble coagulations factors. Pathogenic aPLs are beta2 glycoprotein I (β2GPI)-
dependent and activate complement after an inflammatory stimulus (second hit). Additional variables may affect aPL pathogenicity, such as the ability
of antibodies to modulate different cell signaling and to display diverse epitope specificity and reactivity with modified β2GPI. (b) Obstetric APS. β2GPI-
dependent aPLs may target trophoblast and decidual cells. β2GPI can be present at the uterine level even in non-pregnant animals and it binds to
trophoblast cells (syncytiotrophoblasts). A second hit is not apparently required, and female hormones or the pregnancy itself may be the equivalent
of the second hit described for the vascular manifestations. As in vascular APS, the ability of antibodies to modulate different cell signaling and to display
diverse epitope specificity and reactivity with modified β2GPI may be additional variables that can affect aPL pathogenicity. APC, activated protein
C; C?S, Protein C/S; FII, Factor II; FIXa, Factor IXa, FVIIa, Factor VIIa; FXa, Factor Xa; PT, prothrombin; TF, tissue factor; tPA, tissue plasminogen factor.
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affect signaling pathways in monocytes and trophoblast cell
lines in different ways depending on whether they were ob-
tained from patients with vascular thrombosis or from
women with aPL-related miscarriages only [87]. Hence, the
eventual clinical picture has been linked to autoantibodies
with the same antigen specificity but different biological ef-
fects: induction of a pro-thrombotic and inflammatory
phenotype in monocytes by β2GPI-dependent IgG anti-
bodies from vascular APS patients and inhibition of
trophoblast development by β2GPI-dependent IgG anti-
bodies from obstetric APS patients [87].
It is still unclear whether these different effects can be
related to diverse IgG epitope specificity. The use of
these IgG fractions in animal models of aPL-induced
thrombosis or fetal loss could further support such an
elegant hypothesis in vivo.
Vascular and the obstetric APS have been suggested to
represent two different variants of the syndrome [88].
The most striking difference is represented by the need
of a second hit for triggering thrombosis in naive ani-
mals passively infused with human aPLs, while this is
not apparently required in models of fetal loss. In fact,
the infusion of aPL IgG fractions in pregnant naive mice
can itself induce fetal loss and growth retardation. It has
been recently demonstrated that β2GPI displays a pecu-
liar tissue distribution in resting naive animals, being de-
tectable only at the level of uterine endothelium but not
in other vascularized tissues [89]. So the presence of
anti-β2GPI antibodies can affect pregnancy outcome in
resting animals but it does not trigger any vascular
thrombosis. Animal pre-treatment with small amounts
of lipopolysaccharide may induce the presence of β2GPI
in vascularized tissues and only then can aPLs react with
the target, activate the complement cascade and induce
thrombosis [89]. Accordingly, it has been suggested that
the modulation of β2GPI tissue distribution by inflam-
matory stimuli may represent an additional variable able
to affect the ability of the antibodies to induce the vascu-
lar manifestations of the syndrome [16,89].
Post-transcriptional modifications of β2GPI, such as
oxidation, have been shown to affect autoantibody bind-
ing [90]. For example, autoimmune anti-β2GPI IgG anti-
bodies react more strongly with plates coated with
oxidized β2GPI than antibodies obtained after active
immunization in naive animals. Moreover, plasma levels
of oxidized β2GPI have been found to be increased in
sera of APS patients. Altogether, these findings suggest
that increased levels of post-transcriptionally modified
β2GPI and the higher antibody reactivity against the
modified molecule may affect the biological conse-
quences of aPL binding [90].
In addition, aPLs can be detected in so-called asymp-
tomatic positive carriers who display the persistentpresence of medium to high levels of antibodies but in
whom no clinical events can be documented. It has been
suggested that the second hit cannot take place in these
subjects or that their antibodies display different antigen
specificity. In line with the last hypothesis, the epitope
specificity of the β2GPI-dependent IgG antibodies in
these subjects was found to be more frequently directed
against DIV or DV than against DI as in full-blown APS
sera [68,74]. Since the DI epitope is available for the
autoantibodies on the open molecule only (for example,
when bound to anionic PL monolayers), it has been hy-
pothesized that only these antibodies may be pathogenic.
Figure 1 presents a schematic view of the above dis-
cussed pathogenic mechanisms.
Conclusion
The clinical spectrum of APS is more polymorphic than
it was thought in the past, making the syndrome much
closer to a systemic autoimmune disease. Additional la-
boratory tests have been proposed in order to improve
diagnostic and predictive power, but promising findings
have been reported only for anti-PS/PT and anti-DI
antibodies.
aPLs play a major pathogenic role in inducing clinical
manifestations; however, there is growing evidence that
inflammatory stimuli are pivotal for triggering throm-
bosis, while tissue distribution of the major antigenic
target (β2GPI) as well as its post-transcriptional modifi-
cations or the fine epitope specificity of anti-β2GPI anti-
bodies may influence the type of clinical events or even
their occurrence.
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